CROI 2015 Program and Abstracts

Oral Sessions

Session S-4 Symposium

Room 613

Symposium Conveners Meg C. Doherty , World Health Organization (WHO), Geneva, Switzerland Jeanne M. Marrazzo , University of Washington, Seattle, WA, US 126 The Biology of HIV Transmission: What We ThinkWe Know and HowWe Know It Julie M. Overbaugh Fred Hutchinson Cancer Research Center, Seattle, WA, US 127 HIV Phylogenetics: Lessons for HIV Prevention Christophe Fraser Imperial College London, London, United Kingdom 128 Optimizing ART: Treatment as Prevention in the US: Will It Be Enough? Richard A. Elion Whitman-Walker Health, Washington, DC, US 129 Criminalizing HIV: Recent Experience in the United States and Africa to Update Laws and Policies to Promote the Public Health Jeffrey Crowley Georgetown University, Washington, DC, US Session S-6 Symposium 4:00 pm– 6:00 pm Tuberculosis: Magic Bullets and Moving Targets Target audience: This session is directed to clinicians and scientists interested in the pathogenesis, clinical manifestations, treatment, and prevention of tuberculosis (TB). Level of knowledge: It is assumed that participants are familiar with basic TB epidemiology, clinical features, and treatment. Objectives: At the completion of the session, participants will be able to: • List new techniques for TB diagnosis. • Describe new investigational TB treatment options and strategies. • Describe the unique situation of children and pregnant women infected with TB. Symposium Conveners Alison Grant , London School of Hygiene and Tropical Medicine, London, United Kingdom Ilesh V. Jani , Instituto Nacional de Saúde, Maputo, Mozambique 130 Advances in Mycobacterial Diagnostics Mark P. Nicol University of Cape Town, Cape Town, South Africa 131 NewMedications, Innovative Approaches: Accelerate the TB Regimen Development Pipeline Michael Hoelscher University of Munich, Munich, Germany 132 Tuberculosis in Pregnancy Amita Gupta Johns Hopkins University School of Medicine, Baltimore, MD, US 133 Tuberculosis in Children Anneke C. Hesseling Stellenbosch University, Cape Town, South Africa

4:00 pm– 6:00 pm Making Sense of Sensing: Innate Immunity and HIV Infection Target audience: This session is directed to clinicians and scientists interested in innate immune defenses against HIV, viral countermeasures, and the relevance of the ongoing arms race between both of these for the pathogenesis and spread of AIDS. Level of knowledge: It is assumed that participants are familiar with the basics of HIV replication. Objectives: At the completion of the session, participants will be able to: • Describe the most current understanding of how the human host senses, responds to, and restricts HIV infection, and how the virus evades or counteracts host defense mechanisms. • Appreciate the role of innate immunity in the pathogenesis and spread of HIV disease. Symposium Conveners Nathaniel Landau , NYU School of Medicine, New York, NY, US Jairam R. Lingappa , University of Washington, Seattle, WA, US 122 Role of Tetherin in the Evolution and Spread of HIV-1 Daniel Sauter Ulm University Medical Center, Ulm, Germany 123-A Innate Sensing of HIV-1 in Macrophages Martin R. Jakobsen Aarhus University, Aarhus C, Denmark 124 Innate Sensing and Signaling to HIV-1 in Dendritic Cells Teunis Geijtenbeek Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands 125 How HIV-1 Evades DNA Sensors Vineet KewalRamani National Cancer Institute, Frederick, MD, US Session S-5 Symposium Room 6D 4:00 pm– 6:00 pm Advancing HIV Prevention: Lessons from Biology, Medicine, and Public Health Law Target audience: This session is directed to clinicians, scientists, and policy makers who are interested in developing or implementing HIV prevention programs for maximal benefit. Level of knowledge: It is assumed that participants are familiar with basic HIV epidemiology and transmission, and the effect of antiretroviral drugs for preexposure prophylaxis and treatment as prevention. Objectives: At the completion of the session, participants will be able to: • Determine how new insights into HIV transmission can assist prevention programs. • Describe the barriers to scale up of test-and-treat approaches and how the law can help (or inhibit) prevention efforts.

Wednesday, February 25, 2015 • Oral Sessions

Room 6E

15

CROI 2015